Modified EASL-CLIF criteria that is easier to use and perform better to prognosticate acute-on-chronic liver failure

Table 2 Characteristics of patients with the European Association for the Study of the Liver-Chronic Liver Failure Consortium and modified the European Association for the Study of the Liver-Chronic Liver Failure Consortium organ failures

Variable	Response	All (n = 29618)	EASL-CLIF (n = 14044)	mEACLF (n = 15574)	P value
Age	mean ± SD	52.9 ± 11.6	52.9 ± 11.7	52.9 ± 11.8	0.46
Gender, n (%)	Female	11803 (40)	5601 (40)	6202 (40)	0.92
Race, n (%)	White	20059 (68)	9484 (68)	10575 (68)	0.95
	Black	2530 (9)	1215 (9)	1315 (8)
	Hispanic	5242 (18)	2496 (18)	2746 (18)
	Asian	1129 (4)	540 (4)	589 (4)
	Others	658 (2)	309 (2)	349 (2)
Etiology, n (%)	HCV	3661 (12)	1730 (12)	1931 (12)	0.87
	Alcohol	12537 (42)	5909 (42)	6628 (43)
	HCV + Alcohol	353 (1)	165 (1)	188 (1)
	Cryptogenic	1507 (5)	712 (5)	795 (5)
	Others	11560 (39)	5528 (39)	6032 (39)
Bilirubin	mean ± SD	13.8 ± 12.5	14.1 ± 12.7	13.4 ± 12.3	0.001
Creatinine	mean ± SD	2.11 ± 1.79	2.19 ± 1.81	2.03 ± 1.77	< 0.001
INR	mean ± SD	2.30 ± 1.12	2.29 ± 1.15	2.30 ± 1.08	< 0.001
Encephalopathy, n (%)	Grade 3-4	7088 (24)	3544 (25)	3544 (23)	< 0.001
Respiration, n (%)	Yes	1598 (5)	799 (6)	799 (5)	0.03
Circulatory, n (%)	Yes	2684 (9)	1342 (10)	1342 (9)	0.005
MELD-Na	mean ± SD	29.9 ± 8.1	30.2 ± 8.2	29.7 ± 8.0	< 0.001
Albumin	mean ± SD	3.10 ± 0.74	3.12 ± 0.74	3.08 ± 0.74	< 0.001
Ascites, n (%)	Moderate	13357 (45)	6456 (46)	6901 (44)	0.02

INR: International normalized ratio; EASL-CLIF: European Association for the Study of the Liver-Chronic Liver Failure Consortium; mEACLF: Modified EASL-CLIF; HCV: Hepatitis C virus; MELD: Model for End-stage Liver Disease.